Literature DB >> 24423613

Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.

Tamer E Fandy1, Anchalee Jiemjit, Manjusha Thakar, Paulette Rhoden, Lauren Suarez, Steven D Gore.   

Abstract

PURPOSE: Azanucleoside DNA methyltransferase (DNMT) inhibitors are currently approved by the U.S. Food and Drug Administration for treatment of myelodysplastic syndrome. The relative contributions of DNMT inhibition and other off-target effects to their clinical efficacy remain unclear. Data correlating DNA methylation reversal and clinical response have been conflicting. Consequently, it is necessary to investigate so-called off-target effects and their impact on cell survival and differentiation. EXPERIMENTAL
DESIGN: Flow cytometry was used for cell cycle, apoptosis, and reactive oxygen species (ROS) accumulation analysis. Gene expression analysis was performed using real-time PCR. DNA methylation was detected by methylation-specific PCR. Mitochondrial membrane potential was analyzed using JC-1 dye staining. Western blotting was used for quantitative protein expression analysis.
RESULTS: 5-Aza-2'-deoxycytidine (DAC) induced cell-cycle arrest and apoptosis in leukemia cells. p53 expression was dispensable for DAC-induced apoptosis. DAC induced delayed ROS accumulation in leukemia cells but not in solid tumor cells and p53 expression was dispensable for ROS increase. ROS increase was deoxycytidine kinase dependent, indicating that incorporation of DAC into nuclear DNA is required for ROS generation. ROS accumulation by DAC was caspase-independent and mediated the dissipation of the mitochondrial membrane potential. Concordantly, ROS scavengers diminished DAC-induced apoptosis. DAC induced the expression of different NADPH oxidase isoforms and upregulated Nox4 protein expression in an ATM-dependent manner, indicating the involvement of DNA damage signaling in Nox4 upregulation.
CONCLUSION: These data highlight the importance of mechanisms other than DNA cytosine demethylation in modulating gene expression and suggest investigating the relevance of ROS accumulation to the clinical activity of DAC. ©2014 AACR

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24423613      PMCID: PMC4000016          DOI: 10.1158/1078-0432.CCR-13-1453

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

1.  Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.

Authors:  A R Karpf; B C Moore; T O Ririe; D A Jones
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

2.  JNK1 activity lowers the cellular production of H2O2 and modulates the growth arrest response to scavenging of H2O2 by catalase.

Authors:  Thomas J Preston; James R Woodgett; Gurmit Singh
Journal:  Exp Cell Res       Date:  2003-04-15       Impact factor: 3.905

3.  NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells.

Authors:  Sukhdev S Brar; Zachary Corbin; Thomas P Kennedy; Richelle Hemendinger; Lisa Thornton; Bettina Bommarius; Rebecca S Arnold; A Richard Whorton; Anne B Sturrock; Thomas P Huecksteadt; Mark T Quinn; Kevin Krenitsky; Kristia G Ardie; J David Lambeth; John R Hoidal
Journal:  Am J Physiol Cell Physiol       Date:  2003-04-09       Impact factor: 4.249

4.  p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2.

Authors:  P F Li; R Dietz; R von Harsdorf
Journal:  EMBO J       Date:  1999-11-01       Impact factor: 11.598

5.  Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation.

Authors:  Dong Yeok Shin; You-Soo Park; Kwangmo Yang; Gi-Young Kim; Wun-Jae Kim; Min Ho Han; Ho Sung Kang; Yung Hyun Choi
Journal:  Int J Oncol       Date:  2012-07-05       Impact factor: 5.650

6.  Identification of renox, an NAD(P)H oxidase in kidney.

Authors:  M Geiszt; J B Kopp; P Várnai; T L Leto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

7.  The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine.

Authors:  María Nieto; Enrique Samper; Mario F Fraga; Gonzalo González de Buitrago; Manel Esteller; Manuel Serrano
Journal:  Oncogene       Date:  2004-01-22       Impact factor: 9.867

8.  5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation.

Authors:  Wei-Guo Zhu; Theresa Hileman; Yang Ke; Peichang Wang; Shaoli Lu; Wenrui Duan; Zunyan Dai; Tanjun Tong; Miguel A Villalona-Calero; Christoph Plass; Gregory A Otterson
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

Review 9.  Hydrogen peroxide as second messenger in lymphocyte activation.

Authors:  Michael Reth
Journal:  Nat Immunol       Date:  2002-12       Impact factor: 25.606

10.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2007-06-27       Impact factor: 22.113

View more
  31 in total

Review 1.  ROS and Autophagy: Interactions and Molecular Regulatory Mechanisms.

Authors:  Lulu Li; Jin Tan; Yuyang Miao; Ping Lei; Qiang Zhang
Journal:  Cell Mol Neurobiol       Date:  2015-02-27       Impact factor: 5.046

2.  Interferon gamma/NADPH oxidase defense system in immunity and cancer.

Authors:  Zdenek Hodny; Milan Reinis; Sona Hubackova; Pavla Vasicova; Jiri Bartek
Journal:  Oncoimmunology       Date:  2015-09-01       Impact factor: 8.110

3.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

Authors:  Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Julia Karbach; Michael J Nemeth; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths
Journal:  Leuk Res       Date:  2014-09-10       Impact factor: 3.156

4.  An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Authors:  Nicholas Pulliam; Fang Fang; Ali R Ozes; Jessica Tang; Adeoluwa Adewuyi; Harold Keer; John Lyons; Stephen B Baylin; Daniela Matei; Harikrishna Nakshatri; Feyruz V Rassool; Kathy D Miller; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2018-04-03       Impact factor: 12.531

5.  Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

Authors:  Isabelle Westerlund; Yao Shi; Konstantinos Toskas; Stuart M Fell; Shuijie Li; Olga Surova; Erik Södersten; Per Kogner; Ulrika Nyman; Susanne Schlisio; Johan Holmberg
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

6.  Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells.

Authors:  Hazem E Hassan; Samuel Carlson; Inas Abdallah; Thomm Buttolph; Karen C Glass; Tamer E Fandy
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

7.  Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.

Authors:  Benigno C Valdez; Yang Li; David Murray; Jie Ji; Yan Liu; Uday Popat; Richard E Champlin; Borje S Andersson
Journal:  Exp Hematol       Date:  2015-02-19       Impact factor: 3.084

8.  Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Authors:  Salvia Jain; Abigail Washington; Rebecca Karp Leaf; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Dina Stroopinsky; Athalia Pyzer; Leandra Cole; Myrna Nahas; Arie Apel; Jacalyn Rosenblatt; Jon Arnason; Donald Kufe; David Avigan
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

9.  The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

Authors:  Le Xuan Truong Nguyen; Estelle Troadec; Arjun Kalvala; Bijender Kumar; Dinh Hoa Hoang; Domenico Viola; Bin Zhang; Dang Quan Nguyen; Ibrahim Aldoss; Lucy Ghoda; Elizabeth Budde; Flavia Pichiorri; Steven Rosen; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  J Cell Physiol       Date:  2019-01-08       Impact factor: 6.384

Review 10.  Enhancing venetoclax activity in hematological malignancies.

Authors:  Toshihisa Satta; Steven Grant
Journal:  Expert Opin Investig Drugs       Date:  2020-07-16       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.